Iridium-catalysed C(sp3)−H activation and hydrogen isotope exchange via nitrogen-based carbonyl directing groups

Research output: Contribution to journalArticlepeer-review

Abstract

Growing interest in improved structural diversity within the pharmaceutical industry has led to a focus on more sp3-rich drug frameworks. Meanwhile, spiralling pharmaceutical research and development costs continue to require expedited adsorption, distribution, metabolism, excretion, and toxicity studies, which are heavily reliant on the use of molecules incorporating deuterium and tritium. Herein, we report a an iridium catalyzed C(sp3)−H activation and hydrogen isotope exchange (HIE) methodology capable of utilizing pharmaceutically ubiquitous nitrogen-based carbonyl directing groups. High levels of deuterium incorporation (>80% in 37 of the examples) are demonstrated across a range of substrates (5-, 6- and 7-membered lactams, cyclic carbamates and ureas, acyclic amides), with toleranceof a range of common functional groups (aryl, alkoxy, halogen, ester, alcohol, sulfonamide) and predictable regioselectivity. The applicability of this methodology was demonstrated with up to 98% deuterium incorporation observed in a range of challenging bioactive molecules such as Nefiracetam, Praziquantel, and Unifiram. Density functional theory has provided mechanistic insight into the C-H activation and HIE at both the expected site of incorporation and an unexpected aryl labelling via a 7-membered metallocyclic intermediate.

Original languageEnglish
Number of pages11
JournalAdvanced Synthesis and Catalysis
Early online date17 Apr 2024
DOIs
Publication statusE-pub ahead of print - 17 Apr 2024

Keywords

  • C−H activation
  • hydrogen isotope exchange
  • iridium
  • lactams
  • amides
  • pharmaceuticals

Fingerprint

Dive into the research topics of 'Iridium-catalysed C(sp3)−H activation and hydrogen isotope exchange via nitrogen-based carbonyl directing groups'. Together they form a unique fingerprint.

Cite this